Patients & Physicians
A targeted solution
For patients living with Graves’ disease (GD) and thyroid eye disease (TED), life can feel like a roller coaster. In both conditions, over-stimulation of the TSH receptor by the immune system results in excessive production of thyroid hormones. In the case of GD, this can cause tremors, anxiety, gastrointestinal changes and cardiac issues, including atrial fibrillation. In TED, patients can experience orbital pain, swelling, eye bulging and double vision. Patients with GD and TED have an increased risk of all-cause mortality.
Today, patients can receive drugs with serious toxicities or irreversible treatments that destroy the thyroid tissue. Healthcare providers have long awaited a targeted treatment that can preserve the thyroid and bring patients’ lives back into balance.
We are focused on just that.
Focused on what's possible:
As someone living with Graves’ disease, I understand first-hand the treatment journey patients face—one where too often therapies fail, medications cause serious toxicities, setbacks occur and questions outnumber answers. Having built my career identifying and developing novel therapeutic solutions to biology’s challenges, I feel fortunate to be able to turn that experience into determination to develop new therapies that meaningfully impact the lives of patients living with GD and TED.
Along with the team at Yarrow Bioscience, I face every day with that determination. Our team of seasoned life sciences experts has challenged itself to bring forward a revolutionary new treatment for both Graves’ disease, which has not seen a significant therapeutic advance in more than 70 years, and TED. We believe patients deserve better efficacy with a lower risk of side effects.
We are focused on finding solutions where there have been challenges; answers where there have been questions; balance where there has been dysregulation. I am honored to lead this team and look forward to sharing more on our progress.
Rebecca V. Frey,
President & CEO and Graves’ disease patient
YB-101 targets the central mechanism of GD and TED
YB-101 is designed to bind selectively to TSHR, blocking its activation by the autoantibodies that drive progression of GD and TED.
YB-101 has the potential to provide benefits over current therapies approved or being investigated for GD and TED:
- Specifically targets TSHR
- Rapidly and directly disrupts the underlying disease process in both GD and TED
- Has a potential dosing schedule that may reduce treatment burden with less frequent injections
- Is not expected to cause serious toxicities or immunosuppression
Clinical trial information
YB-101 is currently being studied in clinical trials in both GD and TED.
For Graves’ disease:
- Yarrow Bioscience has initiated a global Phase 2a/2b trial in patients with Graves’ disease (with or without TED) [Clinicaltrials.gov ID: NCT07682896]
- A Phase 1 clinical trial is currently being conducted by our partner GenSci in China [Clinicaltrials.gov ID: NCT07286656]
For thyroid eye disease:
- A Phase 1 clinical trial is currently being conducted by our partner GenSci in China [Clinicaltrials.gov ID: NCT06569758]
Patient resources
Yarrow Bioscience is proud to partner with the Graves’ Disease and Thyroid Foundation to educate and support the patient communities.
